These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 6146334

  • 1. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS, Jackson PR, Freestone S, Ramsay LE, Tucker GT, Woods HF.
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS, Tucker GT, Woods HF.
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.
    Alvan G, von Bahr C, Seidemann P, Sjöqvist F.
    Lancet; 1982 Feb 06; 1(8267):333. PubMed ID: 6120324
    [No Abstract] [Full Text] [Related]

  • 10. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Apr 06; 15(4):443-50. PubMed ID: 6849780
    [Abstract] [Full Text] [Related]

  • 11. Beta-blockers and debrisoquine metaboliser status.
    Jack DB, Kendall MJ.
    Lancet; 1982 Mar 27; 1(8274):741. PubMed ID: 6122034
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
    Davies DS, Kahn GC, Murray S, Brodie MJ, Boobis AR.
    Br J Clin Pharmacol; 1981 Jan 27; 11(1):89-91. PubMed ID: 7213514
    [No Abstract] [Full Text] [Related]

  • 14. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E, Steiner E, Ericsson O, Sjöqvist F.
    Clin Pharmacol Ther; 1987 Mar 27; 41(3):314-9. PubMed ID: 3816019
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.
    Roy SD, Hawes EM, McKay G, Hubbard JW, Midha KK.
    Can J Physiol Pharmacol; 1985 Jul 27; 63(7):778-81. PubMed ID: 3876145
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
    Distlerath LM, Guengerich FP.
    Proc Natl Acad Sci U S A; 1984 Dec 27; 81(23):7348-52. PubMed ID: 6594694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.